Updated:
NestRound
Alexey Repik's NestRound invests proceeds from the R-Pharm sale into early-stage digital health and enterprise software ventures.
NestRound
NestRound was established in 2017 by Alexey Repik, following the sale of his pharmaceutical company R-Pharm, a major player in the Russian and CIS healthcare markets. The office manages capital generated from that transaction, channeling it into technology ventures. Repik's background as an operator in a highly regulated, complex industry informs the office's analytical approach to investment. NestRound's strategy centers on direct early-stage and growth investments, primarily in digital health, enterprise software, and fintech. The office participates in seed and Series A rounds, often as a lead or co-lead investor, and occasionally engages in follow-on funding. Confirmed portfolio companies include BestDoctor, a Russian digital health insurance platform, and RoboJobs, an AI-powered recruitment tool. The geographic focus spans Russia, the CIS, and select opportunities in Europe and Israel. Team size and total deployment figures have not been publicly disclosed. The office operates from Moscow, with a lean structure consistent with single-family tech investment vehicles. There are no publicly known adjacent philanthropic foundations or club memberships tied directly to the NestRound entity as of this record. In January 2024, portfolio company BestDoctor announced a partnership with a major Russian bank to expand its employer-based health services (public record). NestRound's structural differentiator lies in its founder's operational pharmaceutical background, which provides proprietary sourcing advantages in the digital health and biotech-adjacent software sectors. This domain expertise, uncommon among Russian family offices, creates a funnel for deals that combine deep regulatory understanding with scalable technology platforms. Repik remains the sole decision-maker, maintaining a concentrated portfolio reflective of his personal investment thesis.
General information
Firm type
Single Family Office
Year founded
2017
AUM
Undisclosed
Location
Region
Europe
Country
Russia
City
Moscow
Corporate office
Moscow, Russia
Principals
Alexey Repik
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at NestRound?
Alexey Repik, the founder, makes all investment decisions. His background is in pharmaceuticals as the former owner of R-Pharm, a leading Russian drug manufacturer. The office does not publicly list any other investment professionals, indicating a concentrated decision-making structure.
How does NestRound source proprietary deal flow?
NestRound's sourcing advantage stems from Repik's deep network within the Russian and CIS healthcare and technology industries. His operational experience at R-Pharm provides access to health-tech founders operating at the intersection of software and regulatory complexity. The office also leverages its reputation as a founder-friendly capital source.
Is NestRound structured as a single family office or a venture firm?
NestRound operates as a single family office managing Alexey Repik's personal capital. While the firm makes direct venture investments and often co-leads rounds like a venture capital firm, it does not raise external limited partner funds and reports no fund-level fee structures. The posture is that of an institutional VC, but the capital is proprietary.
Does NestRound participate in fund commitments or only direct deals?
NestRound's publicly observable activity is focused on direct investments in early-stage companies. There is no public record of the firm making commitments to external venture capital funds as a limited partner. The mandate appears built for concentrated, high-conviction direct positions where Repik's domain expertise applies.
What investment stages does NestRound typically target?
The firm typically targets seed and Series A rounds. Known portfolio company entries, such as BestDoctor and RoboJobs, were at these early stages. NestRound may participate in follow-on rounds for existing portfolio companies, though these are not publicly systematized as a growth-equity strategy.
Where does the underlying wealth at NestRound come from?
The capital originates from Alexey Repik's sale of R-Pharm, a pharmaceutical company he founded. R-Pharm was one of the largest pharmaceutical firms in Russia, specializing in manufacturing and distributing branded and generic drugs. The exit provided the liquidity pool for NestRound's technology investment program.
What is NestRound's known posture on co-investments alongside external GPs?
NestRound has co-invested alongside other venture capital firms in rounds where it acts as a co-lead or participant. The firm does not publicly describe a formal co-investment program, but its small team and concentrated deal volume suggest that syndicated rounds with like-minded investors are part of the operating model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: